Tafasitamab联合来那度胺作为弥漫性大B细胞淋巴瘤挽救治疗:GELTAMO真实世界经验
该研究描述西班牙99例复发/难治性弥漫性大B细胞淋巴瘤患者接受tafasitamab联合来那度胺(T/L)的真实世界结局,意向治疗组与疗效组的总缓解率分别为51%和61%,中位无进展生存期分别为4.9和10.9个月,中位总生存期分别为12.2和21.8个月,治疗总体耐受良好。
要点
- 意向治疗组与疗效组的总缓解率分别为51%和61%,完全缓解率分别为35%和42%。
- 中位无进展生存期在意向治疗组为4.9个月,在疗效组为10.9个月。
- 来那度胺相对剂量强度显著影响缓解、无进展生存期和总生存期。
核心结论
- T/L耐受良好且有效,不论年龄或合并症如何;研究结果强化了其作为复发/难治性弥漫性大B细胞淋巴瘤关键治疗选择的地位。
研究设计与样本
- 西班牙真实世界研究,共99例患者接受至少1剂tafasitamab(意向治疗组),其中83例完成至少1个完整T/L周期(疗效组)。
主要发现
- 意向治疗组与疗效组的中位随访分别为19.2个月和21.6个月,总缓解率分别为51%和61%,完全缓解率分别为35%和42%。
- 意向治疗组与疗效组的中位无进展生存期分别为4.9个月和10.9个月,中位总生存期分别为12.2个月和21.8个月。
- 中位缓解持续时间未达到,达到完全缓解的患者结局极佳。
- 年龄和累积疾病评定量表评分均不影响生存。
- 仅东部肿瘤协作组体能状态2至4分、双打击淋巴瘤、以及对既往治疗难治/进展的患者与更差的无进展生存期独立相关。
关键数值与推荐
- 来那度胺相对剂量强度显著影响缓解、无进展生存期和总生存期。
- 首次/第二次复发患者获得更好的无进展生存期。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) remains challenging to treat, especially in patients ineligible for intensive therapy or chimeric antigen receptor T cells. Tafasitamab plus lenalidomide (T/L) is an effective option based on the phase 2 L-MIND trial findings, although real-world evidence studies have not consistently confirmed these results. We aimed to describe real-world outcomes of R/R DLBCL treated with T/L in Spain. A total of 99 patients received at least 1 dose of tafasitamab (intent-to-treat [ITT] cohort), with 83 completing at least 1 full cycle of T/L (efficacy cohort). Respectively for ITT and efficacy cohorts, at a median follow-up of 19.2 and 21.6 months, the overall response rate was 51% and 61% (complete response [CR], 35% and 42%). Median duration of response was not reached, and patients achieving a CR had excellent outcomes. The median progression-free survival (PFS) was 4.9 and 10.9 months, and overall survival (OS) was 12.2 and 21.8 months, respectively for both ITT and efficacy cohorts. Neither age nor cumulative illness rating score influenced survival. Better PFS was obtained in first/second relapse but only poor Eastern Cooperative Oncology Group performance status 2 to 4, double-hit lymphoma, and those with refractory/progressing disease after the previous therapy, were independently associated with worse PFS. Treatment was generally well tolerated, with manageable toxicity. Relative dose intensity of lenalidomide significantly affected response, PFS, and OS. In summary, T/L is both well tolerated and effective, irrespective of age or comorbidities. Our findings provide valuable insights into the real-world application of T/L and reinforce its role as a key treatment option for patients with R/R DLBCL.
引用
- Gutierrez A, Zeberio I, Peñalver FJ, et al. Tafasitamab plus lenalidomide as salvage therapy in diffuse large B-cell lymphoma: real-world experience from GELTAMO. Blood Adv. 2025. PMID: 40668613. doi:10.1182/bloodadvances.2025016661
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。